not used title

not used title

Recently, I joined a panel at the Aspen Security Forum to discuss how we can best get vaccines in arms around the globe as we fight COVID-19. As I noted during my remarks, the world is more interconnected than ever before, which means that combating the COVID-19 pandemic can only be successful with effective international cooperation. One of the most important goals of that cooperation is equitable global vaccine distribution. We have to avoid nationalist, protectionist policies that would create inequities, leaving parts of the world substantially under-vaccinated, and limit our ability to slow COVID-19 infections around the globe.

The good news is that we are seeing substantial progress on global vaccine distribution, and the biopharmaceutical industry has made five commitments to ensure we can advance global COVID-19 vaccine equity.

• First, we need to step-up dose sharing. We are working with governments that have significant domestic supplies of COVID-19 vaccine doses to share a meaningful proportion of their doses with low- and lower-middle-income countries in a responsible and timely way through COVAX or other efficient established mechanisms.

• Second, we have to continue to increase manufacturing capacity around the globe. While our industry has globally delivered over 8 billion vaccines to date, we are continuing to undertake substantial efforts to maximize COVID-19 vaccine output without compromising safety and quality.

• Third, we must identify trade barriers for critical input materials and encourage governments to eliminate them. We support the Coalition for Epidemic Preparedness Innovations’ (CEPI’s) effort to create an independent platform that would identify and address gaps in these inputs and facilitate voluntary matchmaking for fill and finish capacity through the newly established COVAX Supply Chain and Manufacturing Task Force. We are also urging governments, in coordination with the World Trade Organization (WTO), to eliminate trade barriers, including import impediments and export restrictions, reduce inappropriate regulatory barriers and to adopt policies that facilitate and expedite cross-border supply.

• Fourth, we are partnering with governments on COVID-19 vaccine deployment, particularly in low- and lower-middle income countries, to ensure that they are ready and able to deploy available doses within their shelf life.

• Fifth, we are prioritizing the development of new COVID-19 vaccines, including vaccines effective against variants of concern. We are also urging governments to guarantee unhindered access to pathogens (e.g., samples and sequences) of any COVID-19 variants to support the development of new vaccines and treatments.

These commitments are essential to the successful continuation of global vaccination efforts. While we have made substantial progress, we realize that there is more work to be done. But it is also essential that we don’t do anything that could hinder our progress in combatting COVID-19 and future public health emergencies. For example, the proposed WTO TRIPS waiver does nothing to address the real global challenges to getting more shots in arms, including last-mile distribution and limited availability of raw materials.

In fact, it would do the opposite. Such a waiver would undermine our global response to the pandemic and potentially compromise patient safety through manufacturers lacking the technical and quality control expertise required. Additionally, it would sow confusion between public and private partners, and further weaken already strained global supply chains. And, perhaps most concerning, it would hinder manufacturers’ ongoing investments to ensure we are prepared for future pandemics and “superbugs” we may face like antimicrobial resistance.

The research behind COVID-19 vaccines is not a recipe that can be simply shared around the world; these are complex products resulting from decades of research and development with complex materials and manufacturing requirements as well as extensive quality control procedures that only qualified manufacturing partners can produce. Proposals to waive IP ignore the real challenges – getting as many people vaccinated as quickly as possible. This requires addressing critical issues around ensuring a qualified health care provider work force and logistical hurdles to deliver vaccines to those who need them.

In contrast, a constructive WTO trade and health initiative – focused on such policies as refraining from export restrictions, eliminating tariffs, improving trade facilitation and strengthening regulatory cooperation and capacity building – could address both current and future challenges. Global health security is strongest when we are working together at the national, regional and global levels.

Biopharmaceutical manufacturers are working tirelessly in partnership with public and private organizations to overcome distribution challenges. We have made incredible progress to date and our commitments provide a path for stepping up our efforts now and for the future. Learn more a PhRMA.org/Coronavirus.

Anne McDonald Pritchett PhD

Anne McDonald Pritchett, Ph.D., is Senior Vice President, Policy and Research, at the Pharmaceutical Research and Manufacturers of America (PhRMA). Her primary focus is overseeing the development of legislative and policy analysis and research studies on a range of issues impacting innovative biopharmaceutical companies including intellectual property issues, FDA policy issues, and other issue areas impacting the environment for innovation. In addition to her public policy work, she and her team lead the development of a range of educational and other materials focused on explaining the R&D process, the value of innovation, and the role and contributions of the innovative biopharmaceutical industry.

Anne McDonald Pritchett PhD

Bayh-Dole: The fuel for America’s innovation engine

September 2, 2026

Why smart vaccine policy matters

August 3, 2026

New study: HPV vaccination helps prevent cervical cancer deaths

July 21, 2026

Setting the record straight: 3 facts about drug patents

July 13, 2026

New PBM principles don't change the fundamental challenge: Access to lower-cost medicines

July 10, 2026

MFN could disrupt the affordable medicines patients depend on

June 18, 2026

Intellectual Property and Hatch-Waxman: A blueprint for American leadership and patient savings

June 2, 2026

New research reinforces the importance of hepatitis B vaccination at birth

May 21, 2026

World Immunization Week: Putting preventable diseases in the past

April 24, 2026

ICYMI: Measles resurgence could cost U.S. nearly $8 billion over five years

April 15, 2026

Argentina sets course to enable innovation by rejecting failed patent rules

March 26, 2026

16 years later: How BPCIA continues to expand competition and lower costs

March 23, 2026

Key context is often missing from the debate over the Patent Trial and Appeal Board

March 20, 2026

MFN undermines U.S. biopharmaceutical innovation

February 25, 2026

Why shifting childhood vaccines to “shared clinical decision-making” puts kids at risk

February 23, 2026

Updated Analysis Underscores the Need for Brazil to Address Patent Backlogs

February 2, 2026

Changes to America’s childhood vaccine schedule fail to protect our nation's kids

January 13, 2026

How post-approval innovation keeps delivering for patients

December 9, 2025

PhRMA calls on USTR to ensure foreign nations pay their fair share

November 4, 2025

New study: Measles setbacks harm health and America’s economy

October 28, 2025

Why the hepatitis B vaccine matters

October 21, 2025

Three things to know about Bayh-Dole: Innovation that pays off for taxpayers

October 9, 2025

Vaccines and autism: Decades of scientific evidence find no link

September 22, 2025

Delivering breakthroughs and lower costs for patients

September 8, 2025

Why the vaccine injury program matters

August 18, 2025

Recognizing the importance of vaccination for American health and security

August 4, 2025

PBMs, not patents, are blocking access to lower-cost medicines

July 23, 2025

Answering common questions on mRNA technology

July 17, 2025

New report: How intellectual property drives U.S. innovation and biopharma's impact

June 30, 2025

What to know about vaccine ingredients: Aluminum and thimerosal

June 24, 2025

New report: Post-approval innovation delivers substantial patient benefits

June 2, 2025

The biopharmaceutical industry is one of the highest contributors to America’s economy among all manufacturers

April 30, 2025

USTR 2025 Special 301 Report corrects course

April 29, 2025

World Immunization Week: Highlighting the importance of vaccines for public health

April 28, 2025

From sound to science: How IP powers innovation in music and hearing

April 25, 2025

How the IRA is impacting the generic drug market

April 8, 2025

3 myths critics get wrong about intellectual property

March 28, 2025

ICYMI: PhRMA submits comments to White House on artificial intelligence

March 17, 2025

What you need to know: Measles and the MMR vaccine

March 10, 2025

New research: Industry sponsored clinical trials contribute billions to state economies

March 6, 2025

Improved treatments continue to lead to declining cancer mortality rates in the U.S.

February 25, 2025

New report sheds light on payment flows in the pharmaceutical supply chain, including the role of 340B and vertical integration

February 13, 2025

Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024

February 3, 2025

Recognizing the value of disease prevention with Dr. Len Friedland from GSK

December 12, 2024

Leveraging the power of vaccines to prevent antimicrobial resistance

October 31, 2024

From the emergency department to the CDC Advisory Committee: Key takeaways from ACIP’s recent meeting

October 30, 2024

The Patient Perspective: Vaccines

October 23, 2024

PhRMA submission calls for USTR to correct course on trade policy, enforcement

October 18, 2024

40 Years of Hatch-Waxman: How Can We Secure its Legacy?

September 24, 2024

40 Years of Hatch-Waxman: How does the Hatch-Waxman Act help patients?

September 23, 2024

40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?

September 19, 2024

New research: American biopharmaceutical investment in R&D drives transformational innovation

September 16, 2024

Biden Administration report debunks myths around patent “evergreening” and “thickets”

September 3, 2024

How to protect your children’s health this school year

August 22, 2024

What to know about the latest effort to break patents using a legally dubious avenue

August 21, 2024

WTAS: Proposed Unsubstantiated USPTO Rule Change is a Threat to American Innovation

August 12, 2024

New Report: Vaccines continue to drive improved health outcomes

July 16, 2024

Showcasing the promise of biopharma at ASCO 2024

June 28, 2024

PhRMA launches education campaign on the benefits of America's IP system

June 26, 2024

ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes

May 30, 2024

Experts discuss the value of IP at Senate Judiciary Committee hearing

May 28, 2024

World Trade Week 2024: Time for a more ambitious U.S. trade agenda

May 23, 2024

World IP Day 2024: Supporting an innovative and sustainable future

April 26, 2024

Why won’t USTR strengthen medical supply chains with America’s allies?

April 25, 2024

World Vaccine Congress: Building on vaccine success

April 1, 2024

International meetings hold big implications for Americans and our innovation ecosystem

February 26, 2024

Proposed march-in framework would chill American innovation

February 7, 2024

PhRMA 2024 Special 301 submission: USTR needs to support American innovation, global access to medicines

January 31, 2024

Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer

January 30, 2024

New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership

January 29, 2024

What they are saying: Experts agree that proposed march-in framework would jeopardize innovation

January 25, 2024

The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings

December 19, 2023

The White House continues to attack American innovation

December 15, 2023

Biden Administration’s Indo Pacific trade dialogue is a missed opportunity to bolster American exports, innovation

November 29, 2023

Misuse of march-in could stifle innovation

November 27, 2023

WHO Pandemic Agreement offers opportunities and risks for American innovators

November 20, 2023

New Report: 1,600 cancer treatments and vaccines in clinical development

November 9, 2023

Word of the Month: The Bayh-Dole Act

November 8, 2023

PhRMA submission: USTR needs more ambition to combat unfair trade barriers

October 24, 2023

What you should know about protecting your health this fall

October 16, 2023

It’s PBMs, not patents, blocking competition 

September 14, 2023

What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain

September 12, 2023

WTAS on reasonable pricing and public-private partnerships

August 8, 2023

Key considerations as Congress works towards PAHPA reauthorization

July 12, 2023

A conversation with Dr. Mike Ybarra on the current state of COVID-19

June 27, 2023

Reject efforts to undermine America’s R&D ecosystem

June 15, 2023

Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth

May 18, 2023

Setting the record straight on the Bayh-Dole Act and March-in

May 10, 2023

World IP Day 2023: Celebrating women leaders in innovation

April 26, 2023

What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary

April 13, 2023

New global analysis shows patient access challenges around the world

April 12, 2023

PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement

March 30, 2023

Celebrating the success of the COVID-19 vaccines, and looking to the future

March 27, 2023

PhRMA submits comments to OSTP on enhancing clinical trial diversity

March 21, 2023

U.S. biopharmaceutical exports support jobs, innovation

March 20, 2023

What we’ve learned from three years of fighting COVID-19

March 20, 2023

Will the administration capitalize on the Indo-Pacific Economic Framework to drive medical innovation?

March 13, 2023

PhRMA submits comments to USPTO highlighting important role of patent system in medicine development

February 23, 2023

U.S. must address IP and market access barriers abroad to protect American innovation

January 31, 2023

Biden administration should prioritize innovation in U.S.-Taiwan Initiative on 21st-Century Trade

January 17, 2023

Word of the Month: What is TRIPS?

November 29, 2022

Expanding TRIPS waiver would jeopardize biopharmaceutical research and development

November 17, 2022

Six ways I-MAK is lying about biopharma patents

November 16, 2022

What you should know about RSV

November 15, 2022

TRIPS waiver expansion risks public health

November 14, 2022

Expanding the WTO intellectual property waiver will hurt American jobs

November 9, 2022

PhRMA submission to USTR calls for urgent defense of American innovation abroad

November 1, 2022

The law driving technology transfer and fostering innovation

October 24, 2022

Word of the Month: Long COVID

October 19, 2022

Don’t take anti-innovation, activist funded academics at their word

October 18, 2022

Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus

October 13, 2022

New report ignores benefits of patent system to innovation and patients

September 30, 2022

Partnerships are driving global COVID-19 treatment access

September 22, 2022

The dangers of expanding the TRIPS waiver

September 19, 2022

ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines

August 16, 2022

Patent policy changes proposed by USPTO and FDA would leave patients behind

July 22, 2022

ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies

July 15, 2022

Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance

July 14, 2022

COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs

July 7, 2022

ICYMI: Antimicrobial resistance spotlighted as growing public health threat

July 6, 2022

Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful

May 23, 2022

ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19

May 13, 2022

ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond

May 9, 2022

A conversation with Barry Greene, CEO of Sage Therapeutics

May 4, 2022

Biden Administration details inadequate protection of American intellectual property and foreign barriers to innovation abroad

April 29, 2022

ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19

April 28, 2022

PhRMA encourages Biden administration to pursue ambitious Indo-Pacific Economic Framework

April 13, 2022

New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year

February 24, 2022

What you need to know about newly authorized COVID-19 antiviral treatments

February 22, 2022

Guest post: Joining forces to combat the COVID-19 mental health crisis

February 17, 2022

Guest Blog: COVID-19 vaccines are the key to keeping kids healthy

February 16, 2022

Research and development continues long after a medicine is initially approved

February 1, 2022

Protecting U.S. innovation abroad to support economic and pandemic recovery

February 1, 2022

ICYMI: New report demonstrates growing global impact of antimicrobial resistance

January 24, 2022

Legislation threatens patent protections and future innovation

January 12, 2022

Navigating the patient experience in the time of COVID-19

December 6, 2021

Understanding breakthrough COVID-19 infections

November 11, 2021

New report highlights importance of IP-intensive manufacturing industries to the U.S. economy

November 1, 2021

PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19

October 29, 2021

The important role of antivirals in the fight against COVID-19

October 6, 2021

Understanding Long COVID-19

September 29, 2021

A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19

September 8, 2021

Patients and innovators lose if the government pursues ‘march-in’

September 7, 2021

The impact of monoclonal antibodies and COVID-19 recovery

September 2, 2021

Recognizing National Immunization Awareness Month

August 31, 2021

Driving further innovation is critical to global vaccine equity

August 24, 2021

Supporting country readiness to boost global vaccine access

August 12, 2021

Ensuring global vaccine equity requires eliminating trade and regulatory barriers

August 5, 2021

Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine

August 4, 2021

Increasing global access to vaccines by optimizing production

July 29, 2021

Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief

July 23, 2021

Guest Post: A patient’s story of the long-term health impacts of COVID-19

July 21, 2021

Dose sharing as a part of the COVID-19 global vaccine equity strategy

July 20, 2021

Promoting global vaccine equity while protecting innovation

July 15, 2021

Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery

July 2, 2021

PhRMA awards $75,000 to fund initiatives to reduce health inequities

July 1, 2021

More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities

June 22, 2021

Americans 12 years of age and older are eligible for COVID-19 vaccines

June 17, 2021

PhRMA hosts first stakeholder workshop on clinical trial diversity

June 11, 2021

Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage Therapeutics

June 9, 2021

A year later: Reflections on the meaning of equity

May 25, 2021

ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios

May 21, 2021

Supporting India during the devastating coronavirus surge

May 20, 2021

New polling shows Americans are sounding the alarm on the TRIPS IP waiver

May 14, 2021

The Biden Administration allows politics to upend a pragmatic pandemic response

May 14, 2021

New report demonstrates development of new medicines relies on private sector expertise and investment

May 10, 2021

PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines

May 6, 2021

Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community

May 5, 2021

Reflecting on Mental Health Awareness Month

May 4, 2021

American leadership on innovation policy is essential to global health progress

May 4, 2021

Patient safety is at the heart of COVID-19 vaccine R&D

April 26, 2021

Data shows that Americans are relying on vaccines to get us through the pandemic

April 22, 2021

ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures

April 12, 2021

Diversifying clinical trials and fighting disease requires equity and trust

April 12, 2021

Key excerpts: PhRMA submits comments to NIST in effort to safeguard intellectual property protections

April 9, 2021

Building confidence in the COVID-19 vaccine through education

March 22, 2021

ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines

March 8, 2021

Intellectual property is the key to vaccine development, manufacturing and technology sharing

March 5, 2021

Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL

February 24, 2021

Fighting variants of COVID-19

February 22, 2021

ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response

February 22, 2021

Top five issues voters want addressed in the administration’s first 100 days

February 18, 2021

The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing

February 12, 2021

Lessons learned from COVID-19: The way we develop new medicines is changing

February 10, 2021

Preserving U.S. innovation worldwide is more important than ever

January 29, 2021

Growing trend: Increased vaccine confidence

January 28, 2021

Election insights: Common ground areas to address Americans’ health care concerns

January 26, 2021

Paper finds gaps in health data are a barrier to health equity

January 11, 2021

New research shows hotspots of inequity relate to increased COVID-19 hospitalizations

January 8, 2021

American biopharmaceutical manufacturing: Fueling economic growth now and for years to come

December 21, 2020

Election insights: Voter priorities in the states

December 17, 2020

Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US

December 16, 2020

Insights from the election: Meeting voters where they are on health care

December 15, 2020

Coming together to fight COVID-19: A conversation with Kabir K. Nath, President & CEO of Otsuka North America Pharmaceutical Bu

December 9, 2020

Guest post: How COVID-19 underscores the importance of public confidence in vaccines

December 7, 2020

Guest Post: Bringing our best to the fight against COVID-19

December 3, 2020

An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb

November 18, 2020